Enlivex Therapeutics (NASDAQ:ENLV) Receives Buy Rating from HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 451.18% from the stock’s previous close.

Enlivex Therapeutics Trading Down 3.8 %

Enlivex Therapeutics stock opened at $1.27 on Tuesday. The stock has a 50 day moving average of $3.30 and a two-hundred day moving average of $2.54. Enlivex Therapeutics has a twelve month low of $1.15 and a twelve month high of $4.59. The stock has a market capitalization of $23.58 million, a price-to-earnings ratio of -0.81 and a beta of 1.02.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.